
Novel non-immunosuppressive approach for Crohn’s
Amorphical has announced positive final long-term follow-up data from its Phase II clinical trial evaluating its investigational nano-amorphous Calcium Carbonate (ACC) therapy, for the treatment of moderate-to-severe Crohn’s disease. The full data analysis, including a cohort of patients who completed follow-up extending up to 48 weeks post-baseline,… Read More
